
The goal of a single-dose treatment for wet AMD
Friday 11 July 2025The standard treatment for wet age-related macular degeneration (wet AMD) is a relentless cycle. To save the sharp, central vision required to read or recognise a face, patients must endure injections directly into the eye, often every one or two months, indefinitely.
This is a continuous, draining battle.
A new approach, now advancing through clinical trials, has been engineered to solve this problem. A single-administration gene therapy, known as 4D-150, has a powerful goal: to significantly reduce this treatment burden with a single dose.
The problem: a relentless cycle of injections Wet AMD occurs when abnormal blood vessels leak fluid beneath the macula, rapidly damaging sight. While current anti-VEGF injections can stop this leakage, their effect is temporary. This ties patients to a demanding schedule that comes at a significant physical, logistical, and emotional cost. It is a management strategy, not a solution.
The scientific goal: a single, durable treatment This burden has driven the search for a better way. The objective is to engineer a treatment that controls the disease for years, not months, from a single administration. This search has led directly to one of the most advanced fields in medicine: gene therapy.
How gene therapy aims to work Instead of repeatedly adding a manufactured drug, gene therapy is designed to turn the eye into its own, self-regulating medicine factory. The process involves delivering a new set of genetic instructions to the retinal cells. The scientific hypothesis is that a single administration could then provide a steady supply of the necessary therapeutic protein for multiple years, right where it is needed most.
The engineering of 4D-150
4D-150 is a clear example of this principled, engineering-led approach. It is designed as a comprehensive attack on key vessel growth factors that drive the disease:
A specialised delivery system: It uses a custom-engineered vector, R100, designed specifically for effective delivery to retinal cells after an injection.
A dual-action payload: The genetic code it carries instructs the retinal cells to produce two different molecules. The first is aflibercept, a proven therapeutic protein. The second is a molecule that inhibits VEGF-C, another key factor in vessel growth.
This is a multi-pronged approach, engineered to block four different factors in the VEGF pathway.
The status: advancing through Phase 3 trials
A promising idea is not a treatment. The journey is long and requires rigorous proof. 4D-150 is now advancing through Phase 3 clinical trials, a pivotal stage of testing required before regulators can consider it for approval. The first data from these trials are not expected until early 2027.
Data from the earlier Phase 2 trial was encouraging. The key finding was a dramatic reduction in treatment burden: patients maintained their vision (with an average gain of +2.2 letters) while requiring over 80% fewer supplemental injections over one year. For newly diagnosed patients, this reduction was 94%.
The most common adverse event was mild, treatable inflammation within the eye, occurring in a small percentage of patients, with no serious vector-related events reported.
What this research could mean for future care
While this therapy is not yet available and its ultimate success and long-term durability are not yet proven, the development of treatments like 4D-150 represents a significant scientific effort to shift the paradigm of wet AMD care.
The objective of this research is a future where the treatment burden is significantly reduced, transforming the standard of care from a lifelong battle into a single administration with the goal of multi-year durability.
Sources
Comments
Post a comment…
A Serious Blog
News and views from around the world on lighting, eyecare and eye conditions.
Twitter: @seriousreaders
Facebook:facebook.com/seriousreaders
Recent posts
- The goal of a single-dose treatment for wet AMD
- A 7- to 8-fold higher risk of vision loss has been linked to this common drink
- Scientists pinpoint key gene in fight against dry AMD
- Bright and dark states of light: Rethinking a fundamental phenomenon
- Exploring photobiomodulation: A potential new direction for dry AMD research
Share your email address and we will keep you up to date as we learn more about light and offer you the best deals.